nach oben

Inflammopharmacology

Erschienen in:

25.04.2018 | Review

Emerging role of semaphorin-3A in autoimmune diseases

verfasst von: Li-Na Liu, Xiao-Mei Li, Dong-Qing Ye, Hai-Feng Pan

Erschienen in: Inflammopharmacology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune diseases (ADs) are featured by the body’s immune responses being directed against its own tissues, resulting in prolonged inflammation and subsequent tissue damage. Currently, the exact pathogenesis of ADs remains not fully elucidated. Semaphorin-3A (Sema3A), a secreted member of semaphorin family, is a potent immunoregulator during all immune response stages. Sema3A has wide expression, such as in bone, connective tissue, kidney, neurons, and cartilage. Sema3A can downregulate ADs by suppressing the over-activity of both T-cell and B-cell autoimmunity. Moreover, Sema3A shows the ability to enhance T-cell and B-cell regulatory properties that control ADs, including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and systemic sclerosis. However, it can also induce ADs when overexpressed. Together, these data strongly suggest that Sema3A plays a pivotal role in ADs, and it may be a promising treatment target for these diseases. In the present review, we focus on the immunological functions of Sema3A and summarize recent studies on the involvement of Sema3A in the pathogenesis of ADs; the discoveries obtained from recent findings may translate into novel therapeutic agent for ADs.

Ae K (1998) Angiogenesis: implication for rheumatoid arthritis. Arthritis Rheum 41:951–962CrossRef

André S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J (2009) Surveillance of antigen-presenting cells by CD4 + CD25 + regulatory T cells in autoimmunity. Am J Pathol 174:1575–1587. https://doi.org/10.2353/ajpath.2009.080987 PubMedPubMedCentralCrossRef

Arizmendi-Vargas J, Carrillo-Ruiz JD, Lopez-Lizarraga ME, Martinez-Menchaca H, Serrato-Ávila JL, Rendón-Molina A, Rivera-Silva G (2011) Multiple sclerosis: an overview of the disease and current concepts of its pathophysiology. J Neurosci Behav Health 3:44–50

Bakke AC, Kirkland PA, Kitridou RC (1983) T lymphocyte subsets in systemic lupus erythematosus. Arthritis Rheum 26:745–750PubMedCrossRef

Barresi V, Tuccari G (2010) Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. Neuropathology 30:537–546. https://doi.org/10.1111/j.1440-1789.2010.01105.x PubMedCrossRef

Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Investig 118:3537–3545. https://doi.org/10.1172/jci36389 PubMedPubMedCentralCrossRef

Bryan C, Howard Y, Brennan P, Black C, Silman A (1996) Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. J Rheumatol 35:1122–1126CrossRef

Catalano A (2006) Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 107:3321–3329. https://doi.org/10.1182/blood-2005-06-2445 PubMedCrossRef

Catalano A (2010) The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol 185:6373–6383. https://doi.org/10.4049/jimmunol.0903527 PubMedCrossRef

Chang A, Tourtellotte WW, Rudick R, Trapp BD (2002) Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346:165–173. https://doi.org/10.1056/nejmoa010994 PubMedCrossRef

Clavel G et al (2007) Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 124:158–164PubMedCrossRef

Committee SN (1999) Unified nomenclature for the semaphorin/collapsins. Cell 97:551–552CrossRef

Costa C, Martínez-Sáez E, Gutiérrez-Franco A, Eixarch H, Castro Z, Ortega-Aznar A, Ramón y Cajal S, Montalban X, Espejo C (2015) Expression of semaphorin 3A, semaphorin 7A and their receptors in multiple sclerosis lesions. Mult Scler J 21:1632–1643. https://doi.org/10.1177/1352458515599848 CrossRef

Cozacov R, Halasz K, Haj T, Vadasz Z (2017) Semaphorin 3A: is a key player in the pathogenesis of asthma. Clin Immunol 184:70–72. https://doi.org/10.1016/j.clim.2017.05.011 PubMedCrossRef

Cvetanovich GL, Hafler DA (2010) Human regulatory T cells in autoimmune diseases. Curr Opin Immunol 22:753–760. https://doi.org/10.1016/j.coi.2010.08.012 PubMedPubMedCentralCrossRef

de Larrinoa IRFF (2015) What is new in systemic lupus erythematosus. Reumatol Clin 11:27–32CrossRef

De Winter F et al (2002) Injury-induced class 3 semaphorin expression in the rat spinal cord. Exp Neurol 175:61–75. https://doi.org/10.1006/exnr.2002.7884 PubMedCrossRef

Delaire S, Billard C, Tordjman R, Chédotal A, Elhabazi A, Bensussan A, Boumsell L (2001) Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration. J Immunol 166:4348–4354PubMedCrossRef

Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15:545–558. https://doi.org/10.1038/nri3871 PubMedCrossRef

Distler O et al (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4:30CrossRef

Distler O et al (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95:109–116PubMedCrossRef

Eixarch H, Gutiérrez-Franco A, Montalban X, Espejo C (2013) Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis. Trends Mol Med 19:157–164. https://doi.org/10.1016/j.molmed.2013.01.003 PubMedCrossRef

Fiore R, Püschel AW (2003) The function of semaphorins during nervous system development. Front Biosci 8:s484–s499PubMedCrossRef

Gagliardini V, Fankhauser C (1999) Semaphorin III can induce death in sensory neurons. Mol Cell Neurosci 14:301–316PubMedCrossRef

Gao H et al (2017a) Expression and clinical significance of semaphorin 3A in serum and mononuclear cells in patients with systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 97:370–374. https://doi.org/10.3760/cma.j.issn.0376-2491.2017.05.010 PubMedCrossRef

Gao H, Ma XX, Guo Q, Zou YD, Zhong YC, Xie LF, Shao M, Zhang XW (2017b) Expression and clinical significance of semaphorin 3A in serum and monouclear cells in patients with systemic lupus erythematous. Natl Med J China 97:370–374

Guan SY, Leng RX, Khan MI, Qureshi H, Li XP, Ye DQ, Pan HF (2017) Interleukin-35: a potential therapeutic agent for autoimmune diseases. Inflammation 40:303–310. https://doi.org/10.1007/s10753-016-0453-9 PubMedCrossRef

Gutiérrez-Franco A et al (2016) Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: implications for a therapeutic design. Clin Immunol 163:22–33. https://doi.org/10.1016/j.clim.2015.12.005 PubMedCrossRef

Huseby ES, Liggitt D, Brabb T, Schnabel B, Öhlén C, Goverman J (2001) A pathogenic role for myelin-specific Cd8 + T cells in a model for multiple sclerosis. J Exp Med 194:669–676. https://doi.org/10.1084/jem.194.5.669 PubMedPubMedCentralCrossRef

Ji JD, Park-Min KH, Ivashkiv LB (2009) Expression and function of semaphorin 3A and its receptors in human monocyte-derived macrophages. Hum Immunol 70:211–217. https://doi.org/10.1016/j.humimm.2009.01.026 PubMedPubMedCentralCrossRef

Kashiwagi H (2005) Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A. Blood 106:913–921. https://doi.org/10.1182/blood-2004-10-4092 PubMedCrossRef

Kawasaki T et al (2002) Requirement of neuropilin 1-mediated Sema3A signals in patterning of the sympathetic nervous system. Development 129:671–680PubMed

Kim SJ (2015) Immunological function of Blimp-1 in dendritic cells and relevance to autoimmune diseases. Immunol Res 63:113–120. https://doi.org/10.1007/s12026-015-8694-5 PubMedPubMedCentralCrossRef

Kolodkin AL, Matthes DJ, Goodman CS (1993) The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75:1389–1399. https://doi.org/10.1016/0092-8674(93)90625-Z PubMedCrossRef

Kremer D, Hartung HP, Küry P (2015) Targeting semaphorins in MS as a treatment strategy to promote remyelination: a tale of mice, rats and men. Mult Scler J 21:1616–1617. https://doi.org/10.1177/1352458515608693 CrossRef

Kumanogoh A et al (2005) Semaphorins in the immune system. Int Congr Ser 1285:202–206. https://doi.org/10.1016/j.ics.2005.08.008 CrossRef

Kurosaka D et al (2010) Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol 37:1121–1128PubMedCrossRef

Lepelletier Y et al (2006) Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization. Eur J Immunol 36:1782–1793. https://doi.org/10.1002/eji.200535601 PubMedCrossRef

Lerang K, Gilboe IM, Gran JT (2012) Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus. Rheumatology (Oxford) 51:663–669. https://doi.org/10.1093/rheumatology/ker318 CrossRef

LeRoy E (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1998) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205

Li HM et al (2016) Emerging role of adipokines in systemic lupus erythematosus. Immunol Res 64:820–830. https://doi.org/10.1007/s12026-016-8808-8 PubMedCrossRef

Loes S, Kettunen P, Kvinnsland IH, Taniguchi M, Fujisawa H, Luukko K (2001) Expression of class 3 semaphorins and neuropilin receptors in the developing mouse tooth. Mech Dev 101:191–194. https://doi.org/10.1016/S0925-4773(00)00545-1 PubMedCrossRef

Lund FE, Randall TD (2010) Effector and regulatory B cells: modulators of CD4 + T cell immunity. Nat Rev Immunol 10:236. https://doi.org/10.1038/nri2729 PubMedPubMedCentralCrossRef

Luo Y, Raible D, Raper JA (1993) Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75:217–227. https://doi.org/10.1016/0092-8674(93)80064-L PubMedCrossRef

Mackiewicz Z, Sukura A, Povilenaite D, Ceponis A, Virtanen I, Hukkanen M, Konttinen YT (2002) Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol 20:641–646PubMed

Majed HH et al (2006) A novel role for Sema3A in neuroprotection from injury mediated by activated microglia. J Neurosci 26:1730–1738. https://doi.org/10.1523/jneurosci.0702-05.2006 PubMedCrossRefPubMedCentral

Messersmith EK, Leonardo ED, Shatz CJ, Tessier-Lavigne M, Goodman M, Kolodkin AL (1995) Semaphorin III can function as a selective chemorepellent to pattern sensory projections in the spinal cord. Neuron 14:949–959PubMedCrossRef

Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M (1999) Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146:233–242PubMedPubMedCentral

Mizui M, Kumanogoh A, Kikutani H (2009) Immune semaphorins: novel features of neural guidance molecules. J Clin Immunol 29:1–11. https://doi.org/10.1007/s10875-008-9263-7 PubMedCrossRef

Mok CC, Lau CS (2003) Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56:481–490PubMedPubMedCentralCrossRef

Moretti S, Procopio A, Lazzarini R, Rippo MR, Testa R, Marra M, Tamagnone L, Catalano A (2008) Semaphorin3A signaling controls Fas (CD95)-mediated apoptosis by promoting Fas translocation into lipid rafts. Blood 111:2290–2299. https://doi.org/10.1182/blood-2007-06096529 PubMedCrossRef

Navarra SV et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731. https://doi.org/10.1016/s0140-6736(10)61354-2 PubMedCrossRef

Negishi-Koga T, Takayanagi H (2012) Bone cell communication factors and semaphorins. Bonekey Rep 1:183PubMedPubMedCentralCrossRef

Okuno T, Nakatsuji Y, Kumanogoh A (2011) The role of immune semaphorins in multiple sclerosis. FEBS Lett 585:3829–3835. https://doi.org/10.1016/j.febslet.2011.03.033 PubMedCrossRef

Olewicz-Gawlik ASD, Samborski W (2016) Soluble semaphorin 3a and neuropilin-1: new markers for dysregulation of angiogenesis in systemic sclerosis. Ann Rheum Dis 75:749. https://doi.org/10.1136/annrheumdis-2016-eular.5233 CrossRef

Osada R, Horiuchi A, Kikuchi N, Ohira S, Ota M, Katsuyama Y, Konishi I (2006) Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 37:1414–1425PubMedCrossRef

Pan HF, Leng RX, Li XP, Zheng SG, Ye DQ (2013a) Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases. Cytokine Growth Factor Rev 24:515–522PubMedCrossRef

Pan HF, Li XP, Zheng SG, Ye DQ (2013b) Emerging role of interleukin-22 in autoimmune diseases. Cytokine Growth Factor Rev 24:51–57. https://doi.org/10.1016/j.cytogfr.2012.07.002 PubMedCrossRef

Perez SG et al (2016) Class 3 semaphorins modulate the invasive capacity of rheumatoid arthritis fibroblast-like synoviocytes. Anna Rheum Dis. https://doi.org/10.1136/annrheumdis-2016-209124.140 CrossRef

Piaton G et al (2011) Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain 134:1156–1167. https://doi.org/10.1093/brain/awr022 PubMedCrossRef

Püschel AW, Adams RH, Betz H (1995) Murine semaphorin D/collapsin is a member of a diverse gene family and creates domains inhibitory for axonal extension. Neuron 14:941–948PubMedCrossRef

Ransohoff RM, Brown MA (2012) Innate immunity in the central nervous system. J Clin Investig 122:1164–1171. https://doi.org/10.1172/jci58644 PubMedPubMedCentralCrossRef

Rezaeepoor M, Shapoori S, Ganjalikhani-hakemi M, Etemadifar M, Alsahebfosoul F, Eskandari N, Mansourian M (2017) Decreased expression of Sema3A, an immune modulator, in blood sample of multiple sclerosis patients. Gene 610:59–63. https://doi.org/10.1016/j.gene.2017.02.013 PubMedCrossRef

Rieger J, Wick W, Weller M (2003) Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. Glia 42:379–389. https://doi.org/10.1002/glia.10210 PubMedCrossRef

Rimar D, Rosner I, Slobodin G, Boulman N, Rozenbaum M, Halasz K, Haj T, Jiries N, Kaly L, Vadasz Z (2014) Semaphorin 3a as a possible immunoregulator in systemic sclerosis. Ann Rheum Dis 73:868. https://doi.org/10.1136/annrheumdis-2014-eular.2948 CrossRef

Rimar D, Rosner I, Slobodin G, Rozenbaum M, Halasz K, Jiries N, Kaly L, Boulman N, Vadasz Z (2015a) Semaphorin 3A, a potential immune regulator in Familial Mediterranean fever. Pediatr Rheumatol 13:O46. https://doi.org/10.1186/1546-0096-13-s1-o46 CrossRef

Rimar D et al (2015b) Semaphorin 3A: an immunoregulator in systemic sclerosis. Rheumatol Int 35:1625–1630. https://doi.org/10.1007/s00296-015-3269-2 PubMedCrossRef

Romano E et al (2016) Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis. Ann Rheum Dis 75:1541–1549. https://doi.org/10.1136/annrheumdis-2015-207483 PubMedCrossRef

Roth L, Koncina E, Satkauskas S, Crémel G, Aunis D, Bagnard D (2008) The many faces of semaphorins: from development to pathology. Cell Mol Life Sci 66:649–666. https://doi.org/10.1007/s00018-008-8518-z CrossRef

Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V (2014) Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44:208–219. https://doi.org/10.1016/j.semarthrit.2014.05.010 PubMedCrossRef

Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20–28. https://doi.org/10.1136/ard.2008.101766 PubMedCrossRef

Scarlato M (2003) Induction of neuropilins-1 and -2 and their ligands, Sema3A, Sema3F, and VEGF, during Wallerian degeneration in the peripheral nervous system. Exp Neurol 183:489–498. https://doi.org/10.1016/s0014-4886(03)00046-3 PubMedCrossRef

Schlahsa L, Zenk J, Aufderbeck S, Figueiredo C, Blasczyk R (2009) Soluble semaphorin 3A regulates the immune response. Hum Immunol 70:s157CrossRef

Solomon BD, Mueller C, Chae WJ, Alabanza LM, Bynoe MS (2011) Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 108:2040–2045. https://doi.org/10.1073/pnas.1008721108 PubMedPubMedCentralCrossRef

Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944. https://doi.org/10.1136/ard.2006.066068 PubMedPubMedCentralCrossRef

Suzuki K, Kumanogoh A, Kikutani H (2008) Semaphorins and their receptors in immune cell interactions. Nat Immunol 9:17–23. https://doi.org/10.1038/ni1553 PubMedCrossRef

Syed YA, Hand E, Mobius W, Zhao C, Hofer M, Nave KA, Kotter MR (2011) Inhibition of CNS remyelination by the presence of semaphorin 3A. J Neurosci 31:3719–3728. https://doi.org/10.1523/jneurosci.4930-10.2011 PubMedCrossRefPubMedCentral

Takagawa S, Nakamura F, Kumagai K, Nagashima Y, Goshima Y, Saito T (2013a) Decreased Semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis. BMC Musculoskelet Disord 14:1–11CrossRef

Takagawa S, Nakamura F, Kumagai K, Nagashima Y, Goshima Y, Saito T (2013b) Decreased semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis. BMC Musculoskelet Disord 14:40. https://doi.org/10.1186/1471-2474-14-40 PubMedPubMedCentralCrossRef

Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, Fujisawa H, Strittmatter SM (1999) Plexin-neuropilin-1 complexes form functional semaphorin-3a receptors. Cell 99:59–69PubMedCrossRef

Takamatsu H, Okuno T, Kumanogoh A (2010a) Regulation of immune cell responses by semaphorins and their receptors. Cell Mol Immunol 7:83–88. https://doi.org/10.1038/cmi.2009.111 PubMedPubMedCentralCrossRef

Takamatsu H et al (2010b) Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II. Nat Immunol 11:594–600. https://doi.org/10.1038/ni.1885 PubMedPubMedCentralCrossRef

Taniguchi M, Yuasa S, Fujisawa H, Naruse I, Saga S, Mishina M, Yagi T (1997) Disruption of semaphorin III/D gene causes severe abnormality in peripheral nerve projection. Neuron 19:519–530. https://doi.org/10.1016/S0896-6273(00)80368-2 PubMedCrossRef

Tran-Van H, Avota E, Bortlein C, Mueller N, Schneider-Schaulies S (2011) Measles virus modulates dendritic cell/T-cell communication at the level of plexinA1/neuropilin-1 recruitment and activity. Eur J Immunol 41:151–163. https://doi.org/10.1002/eji.201040847 PubMedCrossRef

Tubridy N et al (1999) The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology 53:466. https://doi.org/10.1212/wnl.53.3.466 PubMedCrossRef

Vadasz Z, Toubi E (2012) Semaphorin 3A: a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus. Lupus 21:1266–1270. https://doi.org/10.1177/0961203312456753 PubMedCrossRef

Vadasz Z, Toubi E (2013) Semaphorins: their dual role in regulating immune-mediated diseases. Clinic Rev Allerg Immunol 47:17–25. https://doi.org/10.1007/s12016-013-8360-4 CrossRef

Vadasz Z, Attias D, Kessel A, Toubi E (2010) Neuropilins and semaphorins: from angiogenesis to autoimmunity. Autoimmun Rev 9:825–829. https://doi.org/10.1016/j.autrev.2010.07.014 PubMedCrossRef

Vadasz Z, Ben-Izhak O, Bejar J, Sabo E, Kessel A, Storch S, Toubi E (2011) The involvement of immune semaphorins and neuropilin-1 in lupus nephritis. Lupus 20:1466–1473. https://doi.org/10.1177/0961203311417034 PubMedCrossRef

Vadasz Z et al (2012a) Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. Arthritis Res Ther 14:R146. https://doi.org/10.1186/ar3881 PubMedPubMedCentralCrossRef

Vadasz Z, Haj T, Halasz K, Rosner I, Slobodin G, Attias D, Kessel A, Kessler O, Neufeld G, Toubi E (2012b) Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. Arthritis Res Ther 14:1–8CrossRef

Vadasz Z et al (2014) A regulatory role for CD72 expression on B cells in systemic lupus erythematosus. Semin Arthritis Rheum 43:767–771. https://doi.org/10.1016/j.semarthrit.2013.11.010 PubMedCrossRef

Vadasz Z, Peri R, Eiza N, Slobodin G, Balbir-Gurman A, Toubi E (2015a) The expansion of CD25 high IL-10 high FoxP3 high B regulatory cells is in association with SLE disease activity. J Immunol Res 2015:254245. https://doi.org/10.1155/2015/254245 PubMedPubMedCentralCrossRef

Vadasz Z, Rainis T, Nakhleh A, Haj T, Bejar J, Halasz K, Toubi E (2015b) The involvement of immune semaphorins in the pathogenesis of inflammatory bowel diseases (IBDs). PLoS ONE 10:e0125860. https://doi.org/10.1371/journal.pone.0125860 PubMedPubMedCentralCrossRef

Vadasz Z, Rimar D, Toubi E (2015c) A6.14 Semaphorin 3A, an immunoregulator and potential biomarker for disease severity in systemic sclerosis. Ann Rheum Dis 74:A61. https://doi.org/10.1136/annrheumdis-2015-207259.140 CrossRef

Villegas G, Tufro A (2002) Ontogeny of semaphorins 3A and 3F and their receptors neuropilins 1 and 2 in the kidney. Mech Dev 199:S149–S153CrossRef

Williams A et al (2007) Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis? Brain 130:2554–2565. https://doi.org/10.1093/brain/awm202 PubMedCrossRef

Wright DE, White FR, Gerfen RW, Silos-Santiago I, Snider W (1995) The guidance molecule semaphorin III is expressed in regions of spinal cord and periphery avoided by growing sensory axons. J Comp Neurol 361:321–333PubMedCrossRef

Yamamoto M et al (2008) Plexin-A4 negatively regulates T lymphocyte responses. Int Immunol 20:413–420. https://doi.org/10.1093/intimm/dxn006 PubMedCrossRef

Yazdani U, Terman JR (2006) The semaphorins. Genome Biol 7:211. https://doi.org/10.1186/gb-2006-7-3-211 PubMedPubMedCentralCrossRef

Yoshida Y et al (2014) AB0114 Semaphorin3A and semaphorin4d in rheumatoid arthritis. Ann Rheum Dis 72:A820. https://doi.org/10.1136/annrheumdis-2013-eular.2437 CrossRef

Yu C, Gershwin ME, Chang C (2014) Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 49:10–13CrossRef

Yuan X, Cheng G, Malek TR (2014) The importance of regulatory T-cell heterogeneity in maintaining self-tolerance. Immunol Rev 259:103–114. https://doi.org/10.1111/imr.12163 PubMedPubMedCentralCrossRef

Titel: Emerging role of semaphorin-3A in autoimmune diseases
verfasst von: Li-Na Liu
Xiao-Mei Li
Dong-Qing Ye
Hai-Feng Pan
Publikationsdatum: 25.04.2018
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 3/2018
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-018-0484-y

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Potential usefulness of methyl gallate in the treatment of experimental colitis

Oxidative stress as a possible mechanism of statin-induced myopathy

IL-6 signalling pathways and the development of type 2 diabetes

Effect of simvastatin on sensorial, motor, and morphological parameters in sciatic nerve crush induced-neuropathic pain in rats

Professor Giampaolo Velo 31.4.1943–17.8.2017

Is the pharmaceutical industry’s preoccupation with the monotherapy drug model stifling the development of effective new drug therapies?